BioSig Technologies, Inc.: management transactions · United States · SEC (Form 4)

About BioSig Technologies, Inc.

BioSig Technologies, Inc. (ticker: BSGM) is a United States-based company listed on the NASDAQ market in the United States. Historically, BioSig has been positioned as a medical technology company focused on its PURE EP™ platform, a digital signal-processing system designed to improve intracardiac signal visualization for electrophysiologists performing ablation procedures for cardiovascular arrhythmias. In practical terms, the company’s core proposition has been to enhance signal clarity and procedural insight in a highly specialized segment of cardiac electrophysiology. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/03/26/3049719/22558/en/biosig-technologies-confirms-full-compliance-with-nasdaq-requirements-for-continued-listing-on-the-nasdaq-capital-market.html?utm_source=openai)) BioSig was established in the mid-2010s and built its profile as an early-stage medtech developer with limited commercial scale and a recurring need for external capital. That profile has changed materially in 2025. The company announced and then completed a combination with Streamex Exchange Corporation, a move that expanded the business far beyond medical devices. Streamex is described in company communications as a gold tokenization infrastructure company, and the combined group is now targeting real-world asset tokenization, commodity-market infrastructure, and gold-backed treasury initiatives. This makes BSGM a much broader and more complex public-market story than the original BioSig standalone medtech thesis. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/05/05/3074161/22558/en/biosig-enters-into-an-loi-to-merge-with-streamex-exchange-corp.html?utm_source=openai)) From a competitive standpoint, the legacy BioSig business competes in a niche medical-device category where clinical performance, regulatory progress, and hospital adoption determine success. The newer Streamex business, by contrast, competes in the emerging RWA tokenization and digital-asset infrastructure space, where competition is still forming but execution, regulatory approvals, and financial-market partnerships are critical. For investors, that means BSGM now combines two very different risk/reward frameworks: a small-cap medical technology platform with long commercialization timelines, and an early-stage financial technology / tokenization initiative with significant strategic optionality but elevated uncertainty. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/09/08/3146210/22558/en/streamex-exchange-corp-nasdaq-bsgm-creates-a-tokenized-yield-bearing-gold-product-generating-up-to-4-through-exclusive-partnership-with-monetary-metals.html?utm_source=openai)) Recent corporate developments have been the main market catalyst. In 2025, BioSig announced its Streamex transaction, followed by financing initiatives, advisory appointments, and updates on Nasdaq compliance. The company also stated in March 2025 that it had achieved full compliance with Nasdaq listing requirements for continued trading on the Nasdaq Capital Market. Later communications highlighted growth financing intended to support a gold-backed treasury strategy and accelerate RWA tokenization efforts. In short, BioSig has evolved from a single-product medtech name into a Nasdaq-listed United States company pursuing a hybrid strategy spanning electrophysiology technology, gold-linked treasury management, and tokenized commodity-market infrastructure. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/03/26/3049719/22558/en/biosig-technologies-confirms-full-compliance-with-nasdaq-requirements-for-continued-listing-on-the-nasdaq-capital-market.html?utm_source=openai))